WSJ : Fiat Chrysler’s Goal for Alfa Romeo Slipping

Fiat Chrysler’s Goal for Alfa Romeo Slipping

Auto maker to revisit growth plan that counted on Italian sports car, China for big gains

Last June, in a lavish ceremony featuring tenor Andrea Bocelli, Fiat Chrysler Automobiles NV Chief Executive Sergio Marchionne unveiled the first new Alfa Romeo model in six years—the centerpiece of Mr. Marchionne’s plan to revive the group’s jumble of underperforming brands.

Today, the chief executive’s plans to transform Alfa Romeo into a success like Audi are delayed. Meanwhile, economic growth has slowed in China, and tanked in Latin America. Some analysts say the frothy U.S. car market could begin to plateau as soon as this year

All that is laying bare the cracks in Mr. Marchionne’s highly ambitious five-year plan for Fiat Chrysler—called “fantasyland” by Sanford C. Bernstein & Co. analyst Max Warburton—and creating a difficult backdrop for a company struggling to lessen its dependence on selling sport-utility vehicles and pickup trucks to American buyers. The auto maker’s huge debt and thin profit margins add challenges for it in an industry spending heavily on autonomous and electric cars.

Fiat Chrysler’s “business profile isn’t as strong as Ford and GM,” said Yasmina Serghini, a senior credit officer at rating firm Moody’s Investors Service. “The cash flow they generate internally might continue not to be sufficient to meet large capital expenditure requirements.”

At the moment, Fiat Chrysler, which can no longer count on outsize profits from Ferrari, a business it recently spun off, remains almost entirely dependent on its Jeep brand for sales-volume gains. That has Mr. Marchionne’s Italian-American mashup relying heavily on Jeep and the U.S. to offset lackluster results from other brands and regions.

At a time when a soaring U.S. market has sales there growing rapidly, Fiat Chrysler’s operating profit margin remains 40% lower than those of General Motors Co. and Ford Motor Co. Recalls of more than 11 million Fiat Chrysler vehicles last year will further depress earnings, the company has said. At the same time, Fiat Chrysler’s inventory is increasing, according to data provider WardsAuto.com; its 86 days worth of unsold cars on dealer lots in the U.S. at Nov. 30 was almost 50% more than the industry average there.

Later this month, Mr. Marchionne will present a rejiggered version of a 2014 plan that called for a 50% jump in world-wide revenue over five years and a more than doubling of operating profit. The original plan targeted sales of 7 million vehicles in 2018, a 60% increase from 2013.

“We’ll update the plan to reflect things we know now that we didn’t know in 2014,” Mr. Marchionne said earlier this month, while pledging to stick to financial targets even if volumes are lower than the firm had forecast.

Mr. Marchionne has already redirected investments and likely will announce delays in the rollout of new Jeep and Maserati vehicles. He has already dialed back ambitions for Alfa Romeo, but a sales expansion to 400,000 vehicles in 2018 is a cornerstone of his plan to beef up Fiat Chrysler.

Blaming the Chinese slowdown and the country’s import duties, Mr. Marchionne said the €5 billion ($5.46 billion) that Fiat Chrysler had planned to spend on Alfa Romeo though 2018 will now be spread a year or two further out, with delays in several model launches.

“A relatively significant portion of our volume ambitions for 2018 for Alfa were China driven,” Mr. Marchionne said in late October. “We need to be very careful not to create excessive expectations about what China can contribute to [Alfa Romeo’s] objective.”

But some wonder whether the new Alfa Romeo models will ever come to market.

“The structure of the Chinese market hasn’t really changed at all,” said Stephen Reitman, an analyst with Société Générale SA, who points to other problems with the expansion, including Fiat Chrysler’s lack of a local Chinese partner for the Alfa Romeo brand.

Fiat Chrysler declined to comment further.

Mr. Marchionne’s plan to squeeze more cash out of other legacy Fiat brands has stumbled as well. Two new Maserati models meant to compete with German luxury cars have done poorly, with volume and revenue down by a fifth in the third quarter compared with the same period the year before, while Maserati’s operating profit withered to just €12 million from €90 million. The company still plans to launch the first Maserati SUV at the Geneva motor show in March.

All that has left Mr. Marchionne woefully short of money to fund his expansion. Financing vehicle rollouts with debt rather than cash flow is problematic because Fiat Chrysler’s credit ratings from Moody’s and Standard & Poor’s are both below investment grade. The company’s €7.8 billion in net debt makes it expensive to borrow further. By contrast, GM is sitting on $18 billion in net cash and Ford has $9.4 billion.

>>> GSK break-up urged by star fund manager Neil Woodford

GSK break-up urged by star fund manager Neil Woodford

The influential fund manager Neil Woodford called for GlaxoSmithKline (LON:GSK) to be broken up in an interview broadcast on Radio 5, the BBC website reported. Woodford said the GBP 65bn (USD 94bn) UK-based pharmaceuticals group is too complicated and likened it to four FTSE 100-listed businesses joined together.

GSK is not an effective manager of its constituent elements and should concentrate on improving those parts which it can manage better, demerging the others to more experienced people, Woodford said. He added that the business’s current stock price does not reflect the true value of the sum of the company’s parts.

Woodford rarely gives press interviews and when he does his opinions are very influential, the report said. A market report in The Daily Mail noted that following his comments GSK’s shares rose 2%, pushing the stock price to 1371.5p and adding GBP 1.3bn to the company’s value.

BBC, Daily Mail

>>> Shell takeover of BG secures backing of ISS

Shell takeover of BG secures backing of ISS

Royal Dutch Shell (LON:RDSA, RDSB)’s proposed GBP 36bn (USD 52bn) takeover of rival gas and oil company BG Group (LON:BG) has been recommended by the influential proxy advisory group Institutional Shareholder Services, the Financial Times reported. ISS published a report yesterday, 8 January, in which it described the strategic rationale of the deal as “compelling”, while recognising that investors may be anxious because of the current volatility in oil’s spot prices.

When the deal was announced oil was worth approximately USD 56 per barrel but the price has since sunk to less than USD 40, the report noted. The agreed takeover price appears to be fair, according to the ISS report, even once the plummeting price of oil is taken into account.

The deal will be put to the vote by shareholders later this month and approval is required from 75% of BG investors and a majority of Shell’s shareholders, the report said. It added that the ISS report will be a significant help to the management of Shell, which is currently in final meetings with shareholders in the hope of reassuring them the company is not overpaying for BG.

Meanwhile, The Daily Telegraph reported that Standard Life Investments, which owns a 2.1% stake in Shell, announced its intention to vote to block the BG takeover. David Cumming, Standard Life’s head of equities, was quoted stating that the company believes the proposed deal to be “value destructive” as far as Shell investors are concerned.

Financial Times, Daily Telegraph

>>> Standard Life to vote against BG takeover by Shell

Standard Life to vote against BG takeover by Shell 

Standard Life will vote against Shell's takeover of BG, de Telegraaf reported, citing information obtained from Standard LIfe.

Standard Life currently owns 1.7% of Shell's shares, the Dutch language item added. Standard Life claims the conditions around the takeover would cause 'value destruction' for Shell's shareholders, the report noted.

The same report also said that Standard Life has doubts over BG's possesions in Brazil. Shell shareholders can vote on the takeover bid around the end of January, according to De Telegraaf report.

de Telegraaf

>>> Affymetrix Agrees to be acquired by Thermo Fisher for $14.00/shr in cash, va

Affymetrix Agrees to be acquired by Thermo Fisher for $14.00/shr in cash, valuing it at $1.3B 

Thermo Fisher Scientific and Affymetrix, a leading provider of cellular and genetic analysis products, announced that their boards of directors have unanimously approved Thermo Fishers acquisition of Affymetrix for $14.00 per share in cash. The transaction represents a purchase price of approximately $1.3 billion.

Affymetrixs eBioscience offering for cellular analysis will enhance Thermo Fishers leading biosciences capabilities. Specifically, the company specializes in a range of antibodies, multiplex RNA, and protein and single-cell assays. These technologies serve the fast-growing flow cytometry market segment as well as new high-growth applications including single-cell biology, immunotherapy and infectious disease research. Affymetrix adds complementary products in genetic analysis that are used in cytogenetics, genotyping and gene expression. The companys innovative microarray platform will strengthen Thermo Fishers presence in certain clinical and applied markets, including reproductive health and agricultural biotechnology. Affymetrix will benefit from Thermo Fishers access to the biopharma industry through its unique customer value proposition, as well as its world-class e-commerce capabilities and extensive customer channels. Thermo Fisher will also significantly extend the geographic reach of Affymetrixs products by leveraging its market presence and infrastructure in Asia-Pacific, particularly China.The transaction is expected to be immediately accretive to Thermo Fishers adjusted EPS, adding $0.10 of accretion in the first full year of ownership. Thermo Fisher expects to realize total synergies of approximately $70 million by year three following the close, consisting of approximately $55 million of cost synergies and approximately $15 million of adjusted operating income1 benefit from revenue-related synergies.

The transaction, which is expected to be completed by the end of the second quarter of 2016, is subject to the approval of Affymetrix shareholders and the satisfaction of customary closing conditions, including applicable regulatory approvals. Thermo Fisher intends to use cash on hand and short-term debt to finance the transaction.

TMO CEO: For shareholders, we expect the transaction to create value by generating attractive financial returns, including immediate accretion to our adjusted EPS.

Barron's : Dassault Aviation Looks Ready to Cruise

Dassault Aviation Looks Ready to Cruise
The French jet maker was buffeted by lower deliveries than anticipated in 2015. But the backlog is strong, and the stock could rise 25% in a year.

Dow Jones Global Indexes|Global Stock Markets
Aircraft maker Dassault Aviation could be a highflier in 2016. Armed with a strong portfolio of aircraft for the civil and military markets, the French company has good prospects that can push profits to new heights.


Dassault Aviation’s shares (ticker: AM.France), which closed Friday at 1,077.20 euros ($1,172.60), trade for about 19 times estimated 2016 earnings. That sounds lofty, but analysts at Goldman Sachs reckon its earnings before interest and tax could increase at a compound annual rate of 19% from 2015 to 2018. On that basis, the valuation doesn’t look too stretched.
Dassault Aviation could be worth €1,377 in 12 months’ time, according to a sum-of-the-parts calculation based on 2017 estimates by Goldman analysts, pointing to a potential uplift of about 25%.
The stock has gained about 11% in the past 52 weeks, outperforming a 6.3% rise in the Stoxx Europe 600 industrials. It traded as high as €1,338, before slipping back, then lost more altitude in the first few trading days of 2016 after reporting disappointing aircraft-delivery figures for 2015.
Analysts at Credit Suisse offer another way to assess Dassault Aviation’s worth. Subtracting the €3.68 billion of value, its 25% stake in aerospace and defense company Thales (HO.France), and its €3 billion in cash from its €10 billion market cap leaves a stub value of little more than €3 billion for its core business, which seems paltry.
THE TOP-SELLING PRODUCTS of the Paris-based company are its family of Falcon business jets, and the Rafale multirole fighter aircraft. The company delivered 55 new Falcon jets in 2015, down from 66 in 2014. Rafale deliveries fell to eight from 11. The Rafale figures were in line with expectations, but the Falcon deliveries were a problem, a symptom of the weak environment for business jets, particularly from emerging markets.


However, the company’s order backlog is healthy, comprising 91 Falcon jets and 83 Rafales.
After a slow start following its launch in 2001, orders for the Rafale are picking up swiftly. Its versatility has been demonstrated in theaters like Libya, Syria, and Iraq, helping to stir interest from potential buyers.
Egypt last year took delivery of its first three Rafales and another three are due to be handed over in 2016. Dassault Aviation also has taken a deposit from Qatar for 24 Rafales, plus 12 options.
An order for 36 planes from India is expected to be unveiled later this month when French President François Hollande visits that country. The company is negotiating another order with the United Arab Emirates.
Rafale production, currently one plane per month, could rise to two or three per month in 2018, depending on new orders. A couple of new Falcon models, the 8X and the delayed 5X, could provide some impetus to the business jets line between 2016 and 2018.


Research and development spending is expected to drop quite dramatically during this period. As the tail wind from a weaker euro filters through, profit margins could improve. Analysts at Deutsche Bank suggest margins could reach 13% in 2020 compared with 9% in 2014-15, which they identify as the low point.
Dassault is expected to report net income of €451 million in 2016, or €56.44 per share, on sales of €4.20 billion. In 2017, net income is projected to soar to €574 million, or €69.69 per share, on sales of €4.84 billion.
For 2015, the company is expected to report net income of €368 million, or €50.73 per share, on €3.98 billion in sales.
ADDING MORE FUEL to the share price, Airbus Group (AIR.France) is unwinding its holding in Dassault Aviation, increasing the very small free float and thus liquidity.
Dassault Aviation is controlled by the unlisted Dassault Group, which owns more than 50% of the stock. Airbus inherited a 46% holding from one of its founding companies, which left a free float of just a few percent of the outstanding shares.
Airbus considers its stake, currently at 23.4%, a financial holding and has begun to reduce its position. The free float has now swelled to roughly 15%. As a result, daily trading volumes have increased to an average €2.3 million compared with just €200,000 prior to a placement in March. Airbus plans to sell the rest of its shares by the end of 2016, if market conditions are favorable.
For investors, another placement by Airbus will be an opportunity to pick up Dassault Aviation shares.
Stuart Mitchell, managing partner of S.W. Mitchell Capital, counts Dassault among the top 10 holdings in the SWMC European Fund. He could look to boost his position, citing among other things the company’s strong management, conservative accounting, and large cash position.
Mitchell suggests the stock could reach €1,400 a share. “The sky’s the limit, really,” he says.